ERBB2 and breast carcinoma: Recently, neoadjuvant systemic therapy (NST) is adopted more and more in the setting of locally advanced breast cancer and early stage breast cancer with special subtypes like human epidermal growth factor receptor 2 positive (HER2+) and triple negative (TN) [2].